ET

EQS-News: Nagarro posts 12.9% YoY constant-currency revenue growth in 9M 2023

Retrieved on: 
Wednesday, December 6, 2023

In Q3 2023, revenue grew to €234.3 million, up 1.9% YoY from €229.8 million in Q3 2022 and up 6.6% YoY in constant currency.

Key Points: 
  • In Q3 2023, revenue grew to €234.3 million, up 1.9% YoY from €229.8 million in Q3 2022 and up 6.6% YoY in constant currency.
  • Adjusted EBITDA declined to €32.0 million (13.7% of revenue) in Q3 2023 from €48.4 million (21.1% of revenue) in Q3 2022.
  • Revenue grew to €690.6 million in 9M 2023, up 10.4% YoY from €625.4 million in 9M 2022.
  • Adjusted EBITDA declined to €92.4 million (13.4% of revenue) in 9M 2023 from €117.6 million (18.8% of revenue) in 9M 2022.

Disc Medicine to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 8, 2023

WATERTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at the Stifel 2023 Healthcare Conference on Wednesday, November 15th at 11:30 am ET.

Key Points: 
  • WATERTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at the Stifel 2023 Healthcare Conference on Wednesday, November 15th at 11:30 am ET.
  • Disc will also give presentations at the Jefferies London Healthcare Conference on Thursday, November 16th at 9:30 am GMT / 4:30 am ET and the Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30th at 2:30 pm ET.
  • A live webcast of the presentations will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.

Stimvia Announces Completion of Enrollment in Pilot Study for Parkinson's Diseases and Essential Tremor

Retrieved on: 
Wednesday, November 8, 2023

PRAGUE, Nov. 8, 2023 /PRNewswire/ -- Stimvia , a company specializing in the use of neuromodulation for the treatment of chronic diseases, successfully completed recruitment for a pilot study focused on the treatment of Parkinson's disease (PD) and essential tremor (ET).

Key Points: 
  • PRAGUE, Nov. 8, 2023 /PRNewswire/ -- Stimvia , a company specializing in the use of neuromodulation for the treatment of chronic diseases, successfully completed recruitment for a pilot study focused on the treatment of Parkinson's disease (PD) and essential tremor (ET).
  • Patients will be using the URIS® device , which employs a new method called peroneal neuromodulation (eTNM®) for deep brain stimulation.
  • The study assesses the impact on symptoms of patients with PD or ET disorders, as well as the influence of treatment on their quality of life.
  • 24 patients, half with ET and half with PD, are part of the study.

Juniper Networks Announces Date and Webcast Information for Upcoming Investor Events

Retrieved on: 
Wednesday, November 8, 2023

Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced the company will present at the following upcoming investor events:

Key Points: 
  • Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced the company will present at the following upcoming investor events:
    Kevin Hutchins, SVP, Strategy and Corporate Development at Juniper Networks, will present at the Needham Virtual Security, Networking, & Communications Conference, Tuesday, November 14, 2023 at 1:30 pm ET.
  • Ken Miller, EVP and Chief Financial Officer, and Sujai Hajela, EVP, AI-Driven Enterprise at Juniper Networks, will present at the UBS Annual Technology, Media & Telecom Conference, 2:15 pm MT, Wednesday, November 29, 2023, in Scottsdale, AZ.
  • Ken Miller, EVP and Chief Financial Officer at Juniper Networks, will present at the Raymond James TMT and Consumer Conference, 10:20 am ET, Monday, December 4, 2023, in New York, NY.
  • These events will be available live via webcast on the Juniper Networks website: http://investor.juniper.net/ .

 Fuel Tech Reports 2023 Third Quarter Financial Results

Retrieved on: 
Tuesday, November 7, 2023

Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control, and water treatment in utility and industrial applications, today reported financial results for the third quarter ended September 30, 2023 (“Q3 2023”).

Key Points: 
  • Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control, and water treatment in utility and industrial applications, today reported financial results for the third quarter ended September 30, 2023 (“Q3 2023”).
  • “FUEL CHEM operations normalized during Q3 2023 as the unit downtime we experienced in the second quarter of 2023 (“Q2 2023”) caused by temporary maintenance activities and unplanned outages substantially abated.
  • The client reported excellent results from taste tests by local chefs including an absence of trimethylamines (TMA) within the harvest.
  • Adjusted EBITDA was $0.4 million in Q3 2023 compared to Adjusted EBITDA of $0.4 million in Q3 2022.

C3is Inc. reports third quarter and nine months 2023 financial and operating results, with net revenues and net income representing increases of 378% and 1,018% respectively from the previous quarter

Retrieved on: 
Friday, November 3, 2023

Fleet operational utilization of 98.5% for the three months ended September 30, 2023, as our vessels were mainly under time charter employment.

Key Points: 
  • Fleet operational utilization of 98.5% for the three months ended September 30, 2023, as our vessels were mainly under time charter employment.
  • Voyage revenues of $10.1 million for the three months ended September 30, 2023, corresponding to a daily TCEi of $27,903.
  • 378% increase in Net Revenues and 1,637% increase in EBITDA from the second quarter of 2023.
  • Net Income of $3.3 million for the three months ended September 30, 2023.

SEER’S MV TECHNOLOGIES RECEIVES NEW CONTRACTS FOR $1.5MM AND INCREASES ANNUAL MEDIA SUPPLY CONTRACTS

Retrieved on: 
Thursday, November 2, 2023

It is estimated the new systems will collectively use approximately $500,000 of MV’s Axtrap™ media on an annual basis.

Key Points: 
  • It is estimated the new systems will collectively use approximately $500,000 of MV’s Axtrap™ media on an annual basis.
  • This will add significantly to the existing baseline of over $1MM in media sales.
  • MV also recently received a purchase order for an H2SPlus™ for a large Canadian-based food processor.
  • Each project becomes a valuable addition to the more than 140 existing projects already in MV Technologies ’ portfolio throughout North America,” said Tom Jones, President of MV.

Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023

Retrieved on: 
Thursday, November 2, 2023

Overall, 11 of 12 patients responded to treatment (ORR of 92%) and 9 of 12 patients achieved a CRR (75%).

Key Points: 
  • Overall, 11 of 12 patients responded to treatment (ORR of 92%) and 9 of 12 patients achieved a CRR (75%).
  • Overall, 11 of 13 patients responded to treatment (ORR of 85%) and 9 of 13 patients achieved a CRR (69%).
  • New preliminary data (data cut-off: 26 April 2023), for 12 patients enrolled in EUPLAGIA-1, will be presented at ASH (see ASH abstract and poster presentation details below).
  • New preliminary data (data cut-off: 2 May 2023) for 14 patients enrolled in ATALANTA-1 will be presented at ASH (see ASH abstract and poster presentation details below).

AMSC Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Business Outlook

Retrieved on: 
Wednesday, November 1, 2023

AYER, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- AMSC (Nasdaq: AMSC), a leading system provider of megawatt-scale power resiliency solutions that orchestrate the rhythm and harmony of power on the grid™ and protect and expand the capability and resiliency of our Navy’s fleet, today reported financial results for its second quarter of fiscal year 2023 ended September 30, 2023.

Key Points: 
  • Revenues for the second quarter of fiscal 2023 were $34.0 million compared with $27.7 million for the same period of fiscal 2022.
  • AMSC’s net loss for the second quarter of fiscal 2023 was $2.5 million, or $0.09 per share, compared to a net loss of $9.9 million, or $0.35 per share, for the same period of fiscal 2022.
  • Cash, cash equivalents, and restricted cash on September 30, 2023, totaled $24.0 million, compared with $23.1 million at June 30, 2023.
  • In conjunction with this announcement, AMSC management will participate in a conference call with investors beginning at 10:00 a.m. Eastern Time on Thursday, November 2, 2023, to discuss the Company’s financial results and business outlook.

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023

Additional posters representing an expansive body of data demonstrating the potential of Werewolf’s PREDATOR™ platform and INDUKINE™ product candidates will also be presented.

Key Points: 
  • Additional posters representing an expansive body of data demonstrating the potential of Werewolf’s PREDATOR™ platform and INDUKINE™ product candidates will also be presented.
  • Additional posters with preclinical data supporting the PREDATOR platform and INDUKINE product candidates will also be presented at the meeting.
  • These data will provide early insight into the profile of WTX-124 and preferential activation through our INDUKINE design, including additional data since the abstract submission in June,” said Randi Isaacs, M.D., Chief Medical Officer of Werewolf.
  • Pharmacokinetic data as of June 22, 2023, demonstrated WTX-124 sustained prodrug exposure in plasma with low levels of active IL-2.